Trial Profile
A Phase I/II Study of Pembrolizumab (MK-3475) in Children With Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051)
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Hodgkin's disease; Lymphoma; Malignant melanoma; Neuroblastoma; Solid tumours
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms KEYNOTE-051
- Sponsors Merck Sharp & Dohme
- 10 Jan 2024 Planned End Date changed from 6 May 2025 to 25 Oct 2027.
- 10 Jan 2024 Planned primary completion date changed from 6 May 2025 to 25 Oct 2027.
- 29 Mar 2023 Pooled data from KEYNOTE-158, KEYNOTE-164 and KEYNOTE-051 studies presented in a Merck & Co media release.